Remoxipride therapy in treatment resistant schizophrenia

  title={Remoxipride therapy in treatment resistant schizophrenia},
  author={Robert R. Conley and Carol A. Tamminga and J. An Nguyen and R. Hain},
  journal={Schizophrenia Research},
Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol
Amisulpride is at least as effective as haloperidol in the treatment of acute exacerbations of schizophrenia, and is more effective in the Treatment of negative symptoms whilst causing less parkinsonism.
The Behavioural Pharmacology of Typical and Atypical Antipsychotic Drugs
The introduction of the first antipsychotic drugs during the 1950s initiated a search for the mechanism of their therapeutic action to gain insight into the etiology of schizophrenia and related
Overcoming the neuroleptic‐induced deficit syndrome: clinical observations with remoxipride
  • T. Lewander
  • Psychology, Medicine
    Acta psychiatrica Scandinavica. Supplementum
  • 1994
Remoxipride is a selective dopamine D2 antagonist with virtually no activity on other transmitter receptors. It antagonizes dopamine agonists within a wide dose range in animals when it does not
Preclinical findings with new antipsychotic agents: what makes them atypical?
Some new behavioural data is reported and the various mechanisms that can underlie the effect of new atypical antipsychotics are discussed, which are quite different to those exerted by drugs such as haloperidol.